Tyra Biosciences, Inc. (TYRA) stock
TYRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$20.12+0.39 (+1.98%)
Close on Nov 20, 2026Market cap $1.20BP/E –Yield –
Tyra Biosciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Tyra Biosciences's free cash flow for the twelve months ending Jun 30, 2026 was -$109.90M. For fiscal 2025 it was -$95.28M. The highest annual figure on record is -$8.08M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$95.28M | – |
| FY2024 | Dec 31, 2024 | -$70.44M | – |
| FY2023 | Dec 31, 2023 | -$50.91M | – |
| FY2022 | Dec 31, 2022 | -$50.84M | – |
| FY2021 | Dec 31, 2021 | -$24.41M | – |
| FY2020 | Dec 31, 2020 | -$8.08M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$31.14M | – |
| Q1 FY2026 | Mar 31, 2026 | -$32.66M | – |
| Q4 FY2025 | Dec 31, 2025 | -$23.68M | – |
| Q3 FY2025 | Sep 30, 2025 | -$22.42M | – |
| Q2 FY2025 | Jun 30, 2025 | -$23.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.47M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.60M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.95M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.73M | – |
| Q1 FY2024 | Mar 31, 2024 | -$22.16M | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.14M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.23M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.66M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.89M | – |
| Q4 FY2022 | Dec 31, 2022 | -$12.00M | – |
| Q3 FY2022 | Sep 30, 2022 | -$12.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$17.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$9.16M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.13M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.83M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.70M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.74M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.60M | – |
See a number that looks wrong?